- Home
- CIFR vs LEGN Comparison
CIFR vs LEGN Comparison
Compare CIFR & LEGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CIFR
- LEGN
- Stock Information
- Founded
- CIFR 2021
- LEGN 2014
- Country
- CIFR United States
- LEGN United States
- Employees
- CIFR N/A
- LEGN N/A
- Industry
- CIFR Investment Bankers/Brokers/Service
- LEGN Biotechnology: Pharmaceutical Preparations
- Sector
- CIFR Finance
- LEGN Health Care
- Exchange
- CIFR Nasdaq
- LEGN Nasdaq
- Market Cap
- CIFR 6.6B
- LEGN 5.9B
- IPO Year
- CIFR N/A
- LEGN 2020
- Fundamental
- Price
- CIFR $19.16
- LEGN $27.67
- Analyst Decision
- CIFR Strong Buy
- LEGN Strong Buy
- Analyst Count
- CIFR 12
- LEGN 13
- Target Price
- CIFR $24.05
- LEGN $72.92
- AVG Volume (30 Days)
- CIFR 53.8M
- LEGN 1.8M
- Earning Date
- CIFR 11-03-2025
- LEGN 11-12-2025
- Dividend Yield
- CIFR N/A
- LEGN N/A
- EPS Growth
- CIFR N/A
- LEGN N/A
- EPS
- CIFR N/A
- LEGN N/A
- Revenue
- CIFR $206,454,000.00
- LEGN $909,045,000.00
- Revenue This Year
- CIFR $77.60
- LEGN $68.68
- Revenue Next Year
- CIFR $73.72
- LEGN $48.49
- P/E Ratio
- CIFR N/A
- LEGN N/A
- Revenue Growth
- CIFR 35.41
- LEGN 74.75
- 52 Week Low
- CIFR $1.86
- LEGN $25.71
- 52 Week High
- CIFR $25.52
- LEGN $45.30
- Technical
- Relative Strength Index (RSI)
- CIFR 56.89
- LEGN 32.95
- Support Level
- CIFR $13.09
- LEGN $25.71
- Resistance Level
- CIFR $17.56
- LEGN $29.39
- Average True Range (ATR)
- CIFR 1.96
- LEGN 1.53
- MACD
- CIFR -0.06
- LEGN -0.27
- Stochastic Oscillator
- CIFR 66.72
- LEGN 25.03
About CIFR Cipher Mining Inc.
Cipher Mining Inc ia an emerging technology company that operates in the Bitcoin mining ecosystem in the United States. The company is developing a cryptocurrency mining business, specializing in Bitcoin. The company is expanding and strengthening the Bitcoin network's critical infrastructure in the United States.
About LEGN Legend Biotech Corporation
Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.